Earnings summaries and quarterly performance for LABCORP HOLDINGS.
Executive leadership at LABCORP HOLDINGS.
Adam H. Schechter
Detailed
President and Chief Executive Officer
CEO
AO
Akinbolade Oyegunwa
Detailed
Executive Vice President and Chief Information and Technology Officer
AB
Amy B. Summy
Detailed
Executive Vice President and Chief Marketing Officer
AZ
Anita Z. Graham
Detailed
Executive Vice President and Chief Human Resources Officer
BJ
Brian J. Caveney
Detailed
Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer
GA
Glenn A. Eisenberg
Detailed
Executive Vice President
JA
Julia A. Wang
Detailed
Executive Vice President and Chief Financial Officer
LV
Lance V. Berberian
Detailed
Executive Vice President, Special Advisor, Strategy
MS
Mark S. Schroeder
Detailed
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
MD
Megan D. Bailey
Detailed
Executive Vice President and President, Central Laboratories and International
PJ
Peter J. Wilkinson
Detailed
Senior Vice President and Chief Accounting Officer
SD
Sandra D. van der Vaart
Detailed
Executive Vice President, Chief Legal Officer, and Corporate Secretary
Board of directors at LABCORP HOLDINGS.
DG
D. Gary Gilliland
Detailed
Director
GK
Garheng Kong
Detailed
Lead Independent Director
JA
Jeffrey A. Davis
Detailed
Director
KE
Kathryn E. Wengel
Detailed
Director
KB
Kerrii B. Anderson
Detailed
Director
KM
Kirsten M. Kliphouse
Detailed
Director
PB
Paul B. Rothman
Detailed
Director
PM
Peter M. Neupert
Detailed
Director
RP
Richelle P. Parham
Detailed
Director
Research analysts who have asked questions during LABCORP HOLDINGS earnings calls.
Kevin Caliendo
UBS
7 questions for LH
Also covers: AHCO, ALGN, AMWL +15 more
Patrick Donnelly
Citi
7 questions for LH
Also covers: A, AVTR, BIO +22 more
Jack Meehan
Nephron Research LLC
6 questions for LH
Also covers: A, AVTR, BIO +17 more
LG
Lisa Gill
JPMorgan Chase & Co.
6 questions for LH
Also covers: AGL, CAH, CI +13 more
David Westenberg
Piper Sandler
5 questions for LH
Also covers: ADPT, AKYA, BLLN +13 more
Elizabeth Anderson
Evercore ISI
5 questions for LH
Also covers: AGL, ALGN, CAH +23 more
Michael Cherny
Leerink Partners
5 questions for LH
Also covers: ACCD, ALGN, CAH +18 more
AB
Andrew Brackmann
William Blair & Company, L.L.C.
4 questions for LH
Also covers: ADPT, AWH, BDSX +11 more
AH
Ann Hynes
Mizuho Financial Group
4 questions for LH
Also covers: ARDT, BTSG, CI +17 more
EW
Erin Wright
Morgan Stanley
4 questions for LH
Also covers: ALGN, BTSG, CAH +18 more
Tycho Peterson
Jefferies
4 questions for LH
Also covers: A, AVTR, BIO +22 more
Luke Sergott
Barclays
3 questions for LH
Also covers: A, AVTR, BRKR +19 more
Michael Ryskin
Bank of America Merrill Lynch
3 questions for LH
Also covers: A, ALGN, AVTR +28 more
AW
Aaron Wright
Morgan Stanley
2 questions for LH
AB
Andrew Brackman
William Blair
2 questions for LH
Also covers: BLLN, DGX, VCYT
AK
Anna Kozinski
Barclays
2 questions for LH
EC
Eric Coldwell
Robert W. Baird & Co.
2 questions for LH
Also covers: AHCO, CAH, COR +9 more
EP
Eugene Park
Robert W. Baird & Co. Incorporated
2 questions for LH
MC
Michael Cherney
Jefferies Financial Group Inc.
2 questions for LH
Also covers: COR, DGX
PC
Pito Chickering
Deutsche Bank
2 questions for LH
Also covers: ACHC, AHCO, AVAH +18 more
A
Aaron
Bank of America Corporation
1 question for LH
J
Joanna
Evercore Inc.
1 question for LH
John Kim
BMO Capital Markets
1 question for LH
Also covers: AIV, ALX, ARDX +32 more
KR
Kieran Ryan
Deutsche Bank
1 question for LH
Also covers: AHCO, AVAH, BTSG +3 more
MH
Meghan Holtz
Jefferies Financial Group Inc.
1 question for LH
Also covers: AHCO, AVAH, DGX +4 more
MR
Michael Riskin
Bank of America
1 question for LH
Also covers: IDXX, ZTS
S
Skye
Piper Sandler Companies
1 question for LH
SD
Stephanie Davis
Barclays
1 question for LH
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for LH.
Labcorp enters receivables securitization facility
LH
Debt Issuance
- Labcorp Holdings Inc. filed an 8-K on January 28, 2026, reporting the closing of a secured financing arrangement to securitize its laboratory test receivables under a revolving facility.
- The agreement establishes key metrics including the Minimum Funding Threshold and Net Receivables Pool Balance, and requires delivery of monthly Pool Receivables reports.
- As a closing condition, Labcorp delivered audited consolidated financials for FY 2023 and unaudited interim results for Q1 2024, all prepared in accordance with GAAP.
- The company made customary representations and warranties covering compliance with healthcare laws, absence of material overpayments or exclusions, and covenants restricting asset sales, dividends and requiring corporate formalities.
- Events of default include exceeding specified Default Performance Trigger Ratios, Delinquency Ratios or Dilution Ratios, insolvency events, covenant breaches and adverse changes to Pool Receivables.
5 days ago
Affidea acquires majority stake in LabPoint
LH
M&A
- Affidea Group acquired a majority stake in LabPoint S.A. from Lindenhofgruppe to expand its diagnostics and laboratory medicine capabilities in Switzerland.
- LabPoint operates 5 medical laboratories, 4 emergency labs and multiple blood collection points, employing ≈170 professionals specializing in microbiology, molecular biology, genetics and pathology.
- The transaction integrates advanced pathology, cytology and genetics with Affidea’s imaging services, strengthening its precision medicine and oncology care pathways.
- The combined Swiss network now spans 33 centres with a workforce of 870 employees, serving over 265,000 patients annually; Lindenhofgruppe retains a minority stake and remains a key medical partner.
- LabPoint’s Training Academy will continue to offer ≈20 accredited courses per year in gynaecology and obstetrics, supporting professional education.
Jan 14, 2026, 3:32 PM
Labcorp reviews 2025 results and strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
LH
M&A
Guidance Update
Product Launch
- Integration of Invitae turned accretive by Q3 2025 and enabled launch of three new MRD liquid biopsy tests in breast, non-small cell lung, and colon cancers, supporting growth in oncology, women’s health, autoimmune, and neurology.
- Reinforced strong diagnostics fundamentals with a 4.5% organic revenue growth target for 2026, underpinned by durable utilization trends and offset by a 30 bp volume headwind from ACA subsidy expirations.
- Completed 13 hospital and regional lab acquisitions in 2025 with a robust pipeline of deals that meet stringent criteria of year-one accretion and 2–3 year cost-of-capital payback.
- Maintains a balanced capital allocation strategy, with 3.5–4% of revenue in annual capex, a 15–20% dividend payout ratio, and ~$1.1 billion remaining share buyback authorization as of Q3 2025.
- Accelerating efficiency and customer experience improvements through AI and automation, including AI-driven Test Finder, lab process automation, and revenue cycle management enhancements.
Jan 14, 2026, 12:30 AM
Labcorp reviews 2025 execution and sets 2026 growth targets
LH
M&A
Product Launch
Guidance Update
- 2025 delivered strong strategic execution, including 13 hospital acquisitions, integration of Invitae turned accretive by Q3 2025, and roll-out of MRD liquid biopsy tests for breast, lung and colon cancer.
- Diagnostic fundamentals remain robust, with 4.5% organic revenue growth guidance for 2026, driven by demographics, specialty test growth and hospital partnerships.
- Labcorp is advancing AI and digital tools, automating cytology and microbiology workflows, and launching AI-powered Test Finder and appointment scheduling enhancements to boost efficiency and access.
- Government pricing reform: PAMA reimbursement updates delayed at least until January; Labcorp backs bipartisan Results legislation for more representative pricing data.
- Capital deployment: Committed to 3.5–4% of revenue in CapEx, 15–20% dividend payout, and active share buybacks with $1.1 billion remaining; central lab business remains a key growth pillar.
Jan 14, 2026, 12:30 AM
Labcorp details 2025 growth drivers and strategy at JPM Healthcare Conference
LH
Product Launch
M&A
- Launched over 100 new tests in 2025 across oncology, women’s health, autoimmune and neurology, including three MRD liquid biopsy tests sourced from Invitae, bolstering diagnostic innovation.
- Completed 13 hospital and regional lab acquisitions in 2025 under disciplined criteria (accretive in year one; ROI in 2–3 years), with ongoing M&A pipeline supporting network expansion.
- Organic diagnostic growth driven by durable utilization trends (aging, chronic diseases, specialty testing), with an estimated 30 bps volume headwind in 2026 from ACA subsidy expirations.
- PAMA implementation delayed into at least January; industry-backed “RESULTS” legislation proposed to more accurately reform government diagnostic pricing.
- Biopharma Lab Services: central lab business (Phase II/III) remains strong and global; Early Development (<5% revenue) being rationalized via site consolidations and non-core divestiture to improve profitability.
Jan 14, 2026, 12:30 AM
Labcorp expands MRD testing for breast, lung and colon cancer recurrence risk
LH
Product Launch
- Labcorp launched Plasma Detect ID (stage I–III breast & I–IIIA non-small cell lung cancer) and Plasma Detect Genome (stage III colon cancer) MRD tests.
- Both tests detect circulating tumor DNA down to a limit of detection (LOD95) of 0.005%, enabling earlier recurrence detection than traditional imaging.
- Recurrence risk for covered cancers: ~35% in stage III colon, 10–40% in stage I–III breast, and 10–55% in stage I–III NSCLC patients.
- Supported by ongoing/completed clinical studies and recent peer-reviewed publications, reinforcing Labcorp’s leadership in precision oncology monitoring.
Jan 13, 2026, 12:00 PM
Labcorp sells Early Development medical device testing business to NAMSA
LH
M&A
- Labcorp has sold its U.S. Early Development medical device testing business to NAMSA, transferring services including biocompatibility, microbiological, analytical testing, and preclinical research.
- NAMSA, an ARCHIMED portfolio company, will perform future testing and preclinical projects for Labcorp’s former clients at its facilities in Ohio, Minnesota, Georgia, and California.
- The divestiture enables Labcorp to concentrate on its core preclinical drug development and chemical testing operations.
Jan 8, 2026, 1:30 PM
Labcorp reports Q3 2025 results
LH
Earnings
Guidance Update
M&A
- During Q3 2025, Labcorp delivered $3.6 billion in revenue (up 9% YoY), improved enterprise margin by 100 bps, achieved 19% adjusted EPS growth, and generated $281 million of pre-free cash flow.
- The diagnostics segment grew 8.5% (6% organic) with margin expansion of 110 bps, supported by strong organic demand and Invitae accretion; the BLS segment revenue rose 8% (5% constant currency) with a 20 bps margin improvement and a quarterly book-to-bill of 0.9 (TTM 1.09).
- Labcorp signed agreements to acquire select assets of Empire City Laboratories and Laboratory Alliance of Central New York, and to manage Kraus Health inpatient labs (expected to close Q1 2026), and completed select oncology and clinical testing assets from Bio Reference Health.
- Updated full-year 2025 guidance assumes enterprise revenue growth of 7.4%–8%, diagnostics growth of 7.2%–7.8%, BLS growth of 5.7%–7.1%, adjusted EPS of $16.15–$16.50, and free cash flow of $1.165–$1.285 billion.
Oct 28, 2025, 1:00 PM
Labcorp reports Q3 2025 results
LH
Earnings
Guidance Update
M&A
- Delivered $3.6 billion in Q3 revenue (+8.6% YoY), driven by 6.2% organic growth, 1.7% from acquisitions, and 0.7% FX translation.
- Achieved $4.18 adjusted EPS (+19% YoY); adjusted operating income of $513 million (14.4% margin, +100 bps); generated $281 million in free cash flow (+73%).
- Diagnostics labs: $2.8 billion revenue (+8.5% YoY) at 16.3% margin (+110 bps); BLS: $799 million revenue (+8.3% YoY) at 16.5% margin (+20 bps) and $8.6 billion backlog.
- Updated 2025 guidance: enterprise revenue growth of 7.4–8.0%, adjusted EPS $16.15–16.50, and free cash flow $1.165–1.285 billion.
- Advanced M&A strategy with agreements to acquire assets from Empire City Laboratories and Laboratory Alliance of Central New York and partnership with Kraus Health (closing Q1 2026); outreach business deal from Community Health Systems expected by year-end; completed oncology assets acquisition from Bio Reference Health.
Oct 28, 2025, 1:00 PM
Labcorp reports Q3 2025 results
LH
Earnings
Guidance Update
- Reported Q3 2025 revenue of $3,563.5 M, up 8.5% YoY; adjusted EBITDA of $610.3 M, versus $538.9 M in Q3 2024.
- Delivered adjusted EPS of $4.18, up from $3.50 in Q3 2024, reflecting strong operational leverage.
- Diagnostics Laboratories revenue grew 8.5%, driven by 4.7% volume growth and 3.7% price/mix in Q3 2025.
- Biopharma Laboratory Services posted Q3 net orders of $710.8 M (book-to-bill 0.89×) and TTM net orders of $3.34 B as of September 30, 2025.
- Updated 2025 guidance: revenue $13.97–$14.05 B (+7.4–8.0%), adjusted EPS $16.15–$16.50 (+10.8–13.2%), and free cash flow $1.17–$1.29 B (+6.3–17.3%).
Oct 28, 2025, 1:00 PM
Quarterly earnings call transcripts for LABCORP HOLDINGS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more